Healthcare

Noxopharm Limited (ASX:NOX) has reported new research involving its Sofra technology platform, with data presented at the International Society for Respiratory Viruses’ Options for the Control of Influenza XIII Conference in Washington DC.

Memphasys Limited (ASX:MEM) has expanded the European commercial reach of its Felix System after entering an exclusive agreement with Denmark-based NOVIVITAE ApS covering five Nordic markets.

RecordRevenueand accelerating United States adoption have framed the question of whether the market is underestimating this healthcare growth story.

Strong diagnostic trial results and regulatory recognition have put Clarity among the ASX healthcare names investors are watching closely.

Fast test-volume growth and an expanding product pipeline have framed the question of whether the next commercial catalyst could spark a re-rating.

A fundedBalance Sheetand a schedule of clinical readouts have framed the question of whether the market is underestimating this healthcare growth story.

The progress of its pivotal Phase 3 trial and its partnering activity have framed the question of whether the next catalyst could spark a major re-rating.